放射線治療市場：タイプ（製品、サービス）、技術（リニアック、定位リニアック、粒子線治療、コバルト60遠隔治療）、施術（IMRT、IGRT、3D-CRT、LDR、HDR）、用途（前立腺、乳房、肺）、エンドユーザー（病院）別 - 2027年にわたる世界市場予測

Radiotherapy Market by Type (Product, Service), Technology (LINAC, Stereotactic LINAC, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT, 3D-CRT, LDR, HDR), Application (Prostate, Breast, Lung), End User (Hospital) - Global Forecasts to 2027

世界の放射線治療市場は、2022年に63億米ドルと評価され、2027年には予測期間中に5.1%のCAGRで81億米ドルに達すると予測されています。放射線治療における技術の進歩と、がんの発生率の上昇が、この市場の成長を... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年8月1日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	295	273	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界の放射線治療市場は、2022年に63億米ドルと評価され、2027年には予測期間中に5.1%のCAGRで81億米ドルに達すると予測されています。放射線治療における技術の進歩と、がんの発生率の上昇が、この市場の成長を促進する主な要因です。また、放射線治療の利点に対する認識が高まっていることや、がん治療における粒子線治療の利用が増加していることも、同市場の成長を後押しする要因となっています。しかし、特に新興国における医療インフラの不備や、熟練した腫瘍医・放射線科医の不足が、この市場の成長を妨げています。これに加えて、放射線治療装置の高コスト、放射線治療に関する高い複雑性が、予測期間中にこの市場の成長を抑制する要因として予想されています。

"タイプ別のTheserviceセグメントは、2022-2027年の予測期間中に世界の放射線治療市場で最も高い成長率を記録すると予想される"
放射線治療市場は、タイプ別に、製品とサービスに区分されます。2021年は製品分野が最大の市場シェアを占め、2022-2027年はサービス分野が高い成長率を示すと予測されています。サービス分野には、契約後の顧客サポート（保証期間サービス、保証後サービス）、設置サービス、トレーニング、その他の専門的サービスが含まれます。サービス市場分野は、特に北米や欧州などの成熟した市場で高いCAGRを記録すると予想される。

"定位先進電子/コバルト60リニア加速器サブセグメントofLinear Accelerators、外部ビーム放射線治療の中で、予測期間中に著しい成長率を記録する"
放射線治療市場は、oftechnologyに基づいて、外部ビーム放射線治療、内部ビーム放射線治療/小線源治療、全身放射線治療製品に区分されます。外部照射型放射線治療装置は、線形加速器、粒子線治療装置、従来のコバルト60の遠隔治療装置に分類されます。内部放射線治療/小電力治療製品セグメントには、シード、アプリケーター、アフターローダー、IORTシステムなどが含まれます。線形加速器（リニアック）セグメントは、さらに従来型リニアックシステムと定位先進電子/コバルト60リニアックシステムによって特徴付けられています。定位先進リニアックシステム部門は、リニアック部門の中で最も高い成長率を記録すると予想されます。これらのシステムは、さまざまな腫瘍学的処置において治療ターゲットの正確な3Dローカライゼーションを提供します。先進リニアックシステムの主な目的は、健康な周辺構造への被ばくを最小限に抑えながら、腫瘍に高線量の放射線を一度に照射することです。これらのシステムは、リアルタイムの追跡機能により、高い精度と治療時間の短縮を実現することができ、これらのシステムの採用をさらに後押ししています。

「継続的な製品開発と発売が粒子線治療技術分野の成長を後押し" (英語)
放射線治療市場は、技術に基づき、外部ビーム放射線治療と内部ビーム放射線治療に区分されます。外部放射線治療の粒子線治療分野は、他の外部放射線治療分野（リニアック、従来のコバルト60遠隔治療装置など）の中で最も高い成長率を示すと予想されます。継続的な製品開発と研究開発活動も、この市場セグメントの成長を後押ししています。過去3年間に、いくつかの粒子線治療製品が市場に投入された。例えば、現在シーメンス・ヘルスマイナーズAG（ドイツ）傘下のバリアン・メディカル・システムズ社（米国）は、2018年にシングルルーム陽子線治療システム「ProBeam 360°」を発売し、2019年には同製品にマルチルーム構成を導入しています。2020年4月には、P-Cure社（イスラエル）が「P-ARTISシステム」のCEマーキングを取得し、欧州での販売・マーケティングが可能になった。

"2022年～2027年の予測期間において、世界のrdaiotherpay市場において、地域別では中国市場が最も高い成長率で推移すると予測される"
放射線治療市場は、地域別に、北米、欧州、アジア太平洋、中南米、中東・アフリカに区分されます。2021年の世界の放射線治療市場において、アジア太平洋地域は第3位のシェアを占めています。アジア太平洋地域内では、中国が予測期間中に最も高いCAGRで成長すると予測されています。この市場の成長は主に、同国における有利な医療改革と投資によってもたらされます。中国の放射線治療市場の成長ポテンシャルを背景に、さまざまなプレイヤーが同国での存在感を強化するための戦略的イニシアティブをとっています。これらのプレイヤーには、Mevion Medical Systems、IBA、Accuray、Varianなどが含まれ、中国のさまざまなエンドユーザーや利害関係者とパートナーシップ、ライセンス契約、協定、協力枠組み協定を締結し、同国での市場プレゼンスを高めています。

本レポートで参照した主な参加企業の内訳は以下の通りです。
- 企業タイプ別：Tier 1-30%, Tier 2-42%, Tier 3- 28
- 役職別Cレベル-10%、ディレクターレベル-76%、その他-14
- 地域別：北米-40%、ヨーロッパ-30%、アジア太平洋-22%、ラテンアメリカ-6%、中東・アフリカ-2

放射線治療の世界市場における主要企業は、Siemens Healthineers AG（ドイツ）、Elekta（スウェーデン） Accuray Incorporated（米国）、IBA（ベルギー）、ViewRay Technologies, Inc（米国）、日立製作所（日本）、iCAD, Inc.(日本)、iCAD, Inc.（米国）、IsoRay, Inc.（米国）、Mevion Medical Systems, Inc.（米国）、Panacea Medical Technologies Pvt.(インド)、P-cure Ltd.(イスラエル）、ZEISSグループ（ドイツ）などがあります。

調査対象

本レポートでは、放射線治療市場をタイプ、技術、手順、用途、エンドユーザー、地域に基づいて調査しています。また、市場成長に影響を与える要因を網羅し、市場における様々な機会や課題を分析し、市場リーダーのための競争環境の詳細を提供します。さらに、個々の成長トレンドに関してミクロ市場を分析し、主要5地域（およびこれらの地域のそれぞれの国）に関して市場セグメントの収益を予測しています。

本レポートを購入する理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業も市場の動向を把握することができ、ひいてはより大きな市場シェアを獲得するのに役立つものと思われます。本レポートを購入された企業は、以下の戦略の1つまたは複数を組み合わせて、市場での存在感を高めることができます。

本レポートは、以下のポイントに関する洞察を提供します。
市場浸透：放射線治療市場の上位企業が提供する製品ポートフォリオに関する包括的な情報
製品開発/イノベーション：放射線療法市場における今後の動向、R&D活動、製品発売に関する詳細な洞察
市場開発：有利な新興地域に関する包括的な情報
市場の多様化：新製品、成長地域、放射線治療市場の最近の開発に関する詳細な情報
競争力評価：市場セグメント、成長戦略、収益分析、主要な市場プレイヤーの製品に関する詳細な評価

ページTOPに戻る

1 INTRODUCTION 26
1.1 OBJECTIVES OF STUDY 26
1.2 MARKET DEFINITION 27
1.3 STUDY SCOPE 27
1.3.1 MARKETS COVERED 27
1.3.2 GEOGRAPHIES COVERED 28
1.3.3 INCLUSIONS & EXCLUSIONS 28
1.3.4 YEARS CONSIDERED 29
1.4 CURRENCY USED 29
1.5 LIMITATIONS 29
1.6 MARKET STAKEHOLDERS 30
1.7 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH APPROACH 31
FIGURE 1 RADIOTHERAPY MARKET: RESEARCH DESIGN METHODOLOGY 31
2.1.1 SECONDARY RESEARCH 32
2.1.2 PRIMARY RESEARCH 33
2.1.2.1 Primary sources 33
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 34
FIGURE 3 BREAKDOWN OF PRIMARIES: RADIOTHERAPY MARKET 34
2.2 MARKET SIZE ESTIMATION 35
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 35
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 36
2.2.2 USAGE-BASED MARKET ESTIMATION 36
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: GLOBAL RADIOTHERAPY MARKET 37
2.2.3 PRIMARY RESEARCH VALIDATION 37
2.3 DATA TRIANGULATION 38
FIGURE 6 DATA TRIANGULATION 38
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 39
2.4.1 RESEARCH ASSUMPTIONS 39
2.4.2 RESEARCH LIMITATIONS 39
FIGURE 7 RESEARCH LIMITATIONS 39

3 EXECUTIVE SUMMARY 40
FIGURE 8 RADIOTHERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 40
FIGURE 9 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 41
FIGURE 10 EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 42
FIGURE 11 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PROCEDURE, 2022 VS. 2027 (USD MILLION) 43
FIGURE 12 RADIOTHERAPY MARKET SHARE, BY END USER, 2022 VS. 2027 43
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE RADIOTHERAPY MARKET 44
4 PREMIUM INSIGHTS 45
4.1 RADIOTHERAPY MARKET OVERVIEW 45
FIGURE 14 RISING CANCER PREVALENCE WORLDWIDE TO DRIVE GROWTH 45
FIGURE 15 EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022 VS. 2027 (USD MILLION) 45
4.2 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TECHNOLOGY AND REGION (2021) 46
FIGURE 16 LINEAR ACCELERATORS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET 46
4.3 GEOGRAPHIC SNAPSHOT OF RADIOTHERAPY MARKET 47
FIGURE 17 CHINA REGISTERS HIGHEST CAGR DURING THE FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
FIGURE 18 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
5.2.1 DRIVERS 49
5.2.1.1 Technological advancements 49
5.2.1.2 Increasing incidence of cancer worldwide 50
TABLE 1 PROJECTION FOR NEW CANCER CASES BASED ON IARC DATA 50
5.2.1.3 Awareness initiatives on the benefits of radiotherapy 51
5.2.1.4 Growing use of particle therapy for cancer treatment 51
TABLE 2 PARTICLE THERAPY FACILITIES IN CLINICAL OPERATION (AS OF MAY 2022) 52
5.2.2 RESTRAINTS 57
5.2.2.1 Inadequate healthcare infrastructure 57
5.2.2.2 Shortage of skilled oncologists and radiologists 57
5.2.2.3 High cost of radiotherapy devices 58
5.2.2.4 High complexities associated with radiotherapy 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Rising healthcare expenditure across developing countries 59
5.2.3.2 Increasing public-private investments in cancer research 59

5.2.4 CHALLENGES 60
5.2.4.1 Difficulties in visualizing tumors during radiotherapy procedures 60
5.2.4.2 Risk of radiation exposure 60
5.3 PORTER’S FIVE FORCES ANALYSIS 61
5.3.1 OVERVIEW 61
TABLE 3 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 61
5.3.2 THREAT OF NEW ENTRANTS 61
5.3.3 THREAT OF SUBSTITUTES 61
5.3.4 BARGAINING POWER OF SUPPLIERS 62
5.3.5 BARGAINING POWER OF BUYERS 62
5.3.6 DEGREE OF COMPETITION 62
5.4 REGULATORY SCENARIO 62
5.4.1 KEY REGULATORY BODIES & GOVERNMENT AGENCIES IN THE RADIOTHERAPY MARKET 62
TABLE 4 KEY REGULATORY BODIES & GOVERNMENT AGENCIES 62
5.4.2 KEY REGULATORY GUIDELINES 63
5.4.2.1 US 63
TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 64
5.4.2.2 Europe 64
5.4.2.3 Japan 64
TABLE 6 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 65
5.5 REIMBURSEMENT SCENARIO 65
TABLE 7 CPT CODES FOR MAJOR RADIOTHERAPY TREATMENT MODALITY 65
TABLE 8 REIMBURSEMENT FOR RADIOTHERAPY PROCEDURES PER COURSE, 2021 VS. 2022 66
TABLE 9 OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS) TECHNICAL PER PROCEDURE NATIONAL AVERAGE MEDICARE REIMBURSEMENT (2021 VS. 2022) 66
TABLE 10 FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022 67
5.6 ECOSYSTEM COVERAGE 67
5.7 VALUE CHAIN ANALYSIS 68
5.7.1 RESEARCH & DEVELOPMENT 68
5.7.2 PROCUREMENT AND PRODUCT DEVELOPMENT 68
5.7.3 MARKETING, SALES & DISTRIBUTION, AND POST-SALES SERVICES 68
FIGURE 19 VALUE CHAIN ANALYSIS 68
5.8 SUPPLY-CHAIN ANALYSIS 69
5.8.1 PROMINENT COMPANIES 69
5.8.2 SMALL & MEDIUM-SIZED ENTERPRISES 69
5.8.3 END USERS 69
FIGURE 20 SUPPLY-CHAIN ANALYSIS 69

5.9 PRICING ANALYSIS 70
5.9.1 AVERAGE SELLING PRICE OF KEY PLAYERS 70
5.9.2 AVERAGE SELLING PRICE TREND 71
5.10 PATENT DETAILS 72
FIGURE 21 TOP 10 PATENT APPLICANTS FOR RADIOTHERAPY (JANUARY 2012–JUNE 2022) 72
FIGURE 22 TOP 10 PATENT INVENTORS FOR RADIOTHERAPY (JANUARY 2012–JUNE 2022) 72
FIGURE 23 TOP 10 PATENT OWNERS FOR RADIOTHERAPY (JANUARY 2012–JUNE 2022) 73
5.11 TRADE ANALYSIS 73
TABLE 11 IMPORT DATA FOR LINEAR ACCELERATORS (HS CODE 902214), BY COUNTRY, 2017–2021 (USD MILLION) 73
TABLE 12 EXPORT DATA FOR LINEAR ACCELERATORS (HS CODE 902214), BY COUNTRY, 2017–2021 (USD MILLION) 74
5.12 TECHNOLOGY ANALYSIS 75
TABLE 13 IMPORTANT PRODUCT LAUNCHES IN THE RADIOTHERAPY MARKET (JANUARY 2015–JUNE 2022) 75
5.13 KEY CONFERENCES & EVENTS (2022–2023) 76
TABLE 14 RADIOTHERAPY MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS 76
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 77
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 77
5.15 KEY STAKEHOLDERS & BUYING CRITERIA 77
5.15.1 KEY STAKEHOLDERS 77
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR RADIOTHERAPY SYSTEMS 77
TABLE 15 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR PRODUCT SEGMENTS (%) 78
5.16 KEY BUYING CRITERIA BY END USERS 78
TABLE 16 KEY BUYING CRITERIA FOR PRODUCT SEGMENTS 78
6 RADIOTHERAPY MARKET, BY TYPE 79
6.1 INTRODUCTION 80
TABLE 17 RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 80
6.2 PRODUCT 80
6.2.1 LARGE UNTAPPED MARKETS IN EMERGING COUNTRIES DRIVE GROWTH 80
TABLE 18 PRODUCT MARKET, BY REGION, 2020–2027 (USD MILLION) 80
6.3 SERVICE 81
6.3.1 LARGE INSTALLATION BASES IN MATURE MARKETS FUEL DEMAND FOR SERVICES 81
TABLE 19 SERVICE MARKET, BY REGION, 2020–2027 (USD MILLION) 81

7 RADIOTHERAPY MARKET, BY TECHNOLOGY 82
7.1 INTRODUCTION 83
TABLE 20 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 83
TABLE 21 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (UNITS INSTALLED) 83
7.2 EXTERNAL BEAM RADIOTHERAPY (EBRT) 84
TABLE 22 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 23 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (UNITS INSTALLED) 84
TABLE 24 EXTERNAL BEAM RADIOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 85
7.2.1 LINEAR ACCELERATORS 85
TABLE 25 LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85
TABLE 26 LINEAR ACCELERATORS MARKET, BY REGION, 2020–2027 (USD MILLION) 86
7.2.1.1 Conventional linear accelerators 86
7.2.1.1.1 Longer treatment duration limits adoption 86
TABLE 27 CONVENTIONAL LINEAR ACCELERATORS MARKET, BY REGION, 2020–2027 (USD MILLION) 87
7.2.1.2 Stereotactic advanced electron/cobalt-60 linear accelerators 87
TABLE 28 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 29 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY REGION, 2020–2027 (USD MILLION) 88
7.2.1.2.1 CyberKnife 88
7.2.1.2.1.1 CyberKnife offers precise radiation delivery with robotic correction capabilities 88
TABLE 30 CYBERKNIFE MARKET, BY REGION, 2020–2027 (USD MILLION) 89
7.2.1.2.2 Gamma Knife 89
7.2.1.2.2.1 Ongoing product development and launches support demand 89
TABLE 31 GAMMA KNIFE MARKET, BY REGION, 2020–2027 (USD MILLION) 90
7.2.1.2.3 TomoTherapy 90
7.2.1.2.3.1 High installation and maintenance costs limit adoption 90
TABLE 32 TOMOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 91
7.2.2 PARTICLE THERAPY SYSTEMS 91
TABLE 33 PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 34 PARTICLE THERAPY SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION) 92
7.2.2.1 Cyclotrons 92
7.2.2.1.1 Cyclotrons deliver a continuous stream of particles to a tumor site, enhancing outcomes 92
TABLE 35 CYCLOTRONS MARKET, BY REGION, 2020–2027 (USD MILLION) 94
7.2.2.2 Synchrotrons 94
7.2.2.2.1 Increasing investments in synchrotron facilities drive market 94
TABLE 36 SYNCHROTRONS MARKET, BY REGION, 2020–2027 (USD MILLION) 95
7.2.2.3 Synchrocyclotrons 95
7.2.2.3.1 High space requirements limit widespread adoption 95
TABLE 37 SYNCHROCYCLOTRONS MARKET, BY REGION, 2020–2027 (USD MILLION) 95
7.2.3 CONVENTIONAL COBALT-60 TELETHERAPY UNITS 96
7.2.3.1 Complex dose delivery planning and radiation exposure limit market adoption 96
TABLE 38 CONVENTIONAL COBALT-60 TELETHERAPY UNITS MARKET, BY REGION, 2020–2027 (USD MILLION) 96
7.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 97
TABLE 39 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 97
TABLE 40 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 97
7.3.1 SEEDS 98
7.3.1.1 Adverse side-effects associated with seeds limit adoption 98
TABLE 41 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY SEEDS MARKET, BY REGION, 2020–2027 (USD MILLION) 98
7.3.2 APPLICATORS 99
7.3.2.1 Manual applicators pose a high risk of radiation exposure 99
TABLE 42 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATORS MARKET, BY REGION, 2020–2027 (USD MILLION) 99
7.3.3 AFTERLOADERS 100
7.3.3.1 Proper positioning and better control of isotopes in modern afterloaders drive demand 100
TABLE 43 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY AFTERLOADERS MARKET, BY REGION, 2020–2027 (USD MILLION) 100
7.3.4 IORT SYSTEMS 101
7.3.4.1 Rising adoption of electronic brachytherapy procedures supports growth 101
TABLE 44 IORT SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION) 101
7.4 SYSTEMIC RADIOTHERAPY 102
7.4.1 HIGH RISK OF RADIATION EXPOSURE LIMITS ADOPTION 102
7.4.2 IOBENGUANE (I-131) 102
7.4.3 SAMARIUM-153 102
7.4.4 RHENIUM-186 103
7.4.5 OTHER SYSTEMIC RADIOTHERAPY PRODUCTS 103
8 RADIOTHERAPY MARKET, BY APPLICATION 104
8.1 INTRODUCTION 105
TABLE 45 RADIOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 105
8.2 EXTERNAL BEAM RADIOTHERAPY APPLICATION 106
TABLE 46 EXTERNAL BEAM RADIOTHERAPY APPLICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 106
TABLE 47 EXTERNAL BEAM RADIOTHERAPY APPLICATION MARKET, BY REGION, 2020–2027 (USD MILLION) 106
8.2.1 PROSTATE CANCER 107
8.2.1.1 High incidence rate and efficiency of EBRT for prostate cancer treatment support growth 107
TABLE 48 EXTERNAL BEAM RADIOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION) 107
8.2.2 BREAST CANCER 108
8.2.2.1 Therapeutic benefits of EBRT for breast cancer support market growth 108
TABLE 49 EXTERNAL BEAM RADIOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION) 108
8.2.3 LUNG CANCER 109
8.2.3.1 Radiotherapy can be used as adjuvant therapy for lung cancer 109
TABLE 50 EXTERNAL BEAM RADIOTHERAPY MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION) 109
8.2.4 HEAD & NECK CANCER 110
8.2.4.1 Noninvasiveness of EBRT in treatment of head & neck cancers drives growth 110
TABLE 51 EXTERNAL BEAM RADIOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2020–2027 (USD MILLION) 110
8.2.5 COLORECTAL CANCER 111
8.2.5.1 High incidence of colorectal cancer to support market growth 111
TABLE 52 EXTERNAL BEAM RADIOTHERAPY MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION) 111
8.2.6 OTHER CANCERS 112
TABLE 53 EXTERNAL BEAM RADIOTHERAPY MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION) 112
8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 113
TABLE 54 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 55 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATION MARKET, BY REGION, 2020–2027 (USD MILLION) 113
8.3.1 PROSTATE CANCER 114
8.3.1.1 Precision of brachytherapy drives market growth 114
TABLE 56 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION) 114
8.3.2 GYNECOLOGICAL CANCER 115
8.3.2.1 Availability of alternatives to hinder adoption of brachytherapy 115
TABLE 57 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2020–2027 (USD MILLION) 115
8.3.3 BREAST CANCER 116
8.3.3.1 Brachytherapy is a replacement for traditional whole-breast external radiation therapy 116
TABLE 58 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION) 116
8.3.4 CERVICAL CANCER 117
8.3.4.1 Combination treatment of brachytherapy and chemotherapy supports market growth 117
TABLE 59 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR CERVICAL CANCER, BY REGION, 2020–2027 (USD MILLION) 117
8.3.5 PENILE CANCER 118
8.3.5.1 Interstitial brachytherapy and plesiobrachytherapy are used in penile cancer treatment 118
TABLE 60 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR PENILE CANCER, BY REGION, 2020–2027 (USD MILLION) 118
8.3.6 OTHER CANCERS 119
TABLE 61 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION) 119
9 RADIOTHERAPY MARKET, BY PROCEDURE 120
9.1 INTRODUCTION 121
TABLE 62 RADIOTHERAPY MARKET, BY PROCEDURE, 2020–2027 (USD MILLION) 121
9.2 EXTERNAL BEAM RADIOTHERAPY 121
TABLE 63 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 64 EXTERNAL BEAM RADIOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 122
9.3 IMAGE-GUIDED RADIOTHERAPY (IGRT) 123
9.3.1 IMAGE-GUIDED RADIOTHERAPY IS USED TO TREAT DEEP-SEATED TUMORS 123
TABLE 65 IMAGE-GUIDED RADIOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 123
9.3.2 INTENSITY-MODULATED RADIOTHERAPY 124
9.3.2.1 IMRT modulates radiation intensity and conforms radiation doses in a tumor 124
TABLE 66 INTENSITY-MODULATED RADIOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 124
9.3.3 3D CONFORMAL RADIOTHERAPY 125
9.3.3.1 Multiple beams with 3D-CRT offer dose escalation within target volume 125
TABLE 67 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 125
9.3.4 STEREOTACTIC THERAPY 126
9.3.4.1 Stereotactic therapy offers minimally invasive alternatives to ablation surgeries 126
TABLE 68 STEREOTACTIC THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 126
9.3.5 PARTICLE THERAPY 127
9.3.5.1 Adoption of particle therapy as a primary mode of cancer treatment supports market growth 127
TABLE 69 PARTICLE THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 127

9.4 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 128
TABLE 70 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 71 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 128
9.4.1 HIGH-DOSE-RATE BRACHYTHERAPY 129
9.4.1.1 HDR brachytherapy delivers radiation dose through temporarily positioned applicators 129
TABLE 72 HIGH-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 129
9.4.2 LOW-DOSE-RATE BRACHYTHERAPY 130
9.4.2.1 Lower risk of radiation exposure to surrounding tissues drives market growth 130
TABLE 73 LOW-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 130
9.4.3 PULSED-DOSE-RATE BRACHYTHERAPY 131
9.4.3.1 Pulsed-dose-rate brachytherapy combines benefits of HDR and LDR brachytherapy 131
TABLE 74 PULSED-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 131
9.5 SYSTEMIC RADIOTHERAPY 131
9.5.1 HIGH COST OF RADIOPHARMACEUTICALS AND HIGH RISK OF RADIATION EXPOSURE LIMIT UTILIZATION OF THIS PROCEDURE 131
9.5.2 INTRAVENOUS RADIOTHERAPY 132
9.5.3 ORAL RADIOTHERAPY 132
9.5.4 INSTILLATION RADIOTHERAPY 132
10 RADIOTHERAPY MARKET, BY END USER 133
10.1 INTRODUCTION 134
TABLE 75 RADIOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 134
10.2 HOSPITALS 135
10.2.1 GROWING ADOPTION OF RADIOTHERAPY PROCEDURES DRIVES MARKET GROWTH 135
TABLE 76 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 135
10.3 INDEPENDENT RADIOTHERAPY CENTERS 136
10.3.1 LOWER OPERATING COSTS AND CONVENIENCE SUPPORT MARKET GROWTH 136
TABLE 77 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2020–2027 (USD MILLION) 136
11 RADIOTHERAPY MARKET, BY REGION 137
11.1 INTRODUCTION 138
TABLE 78 RADIOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 138
11.2 NORTH AMERICA 139
FIGURE 26 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT 139
TABLE 79 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 80 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 140
TABLE 81 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 82 NORTH AMERICA: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 83 NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 84 NORTH AMERICA: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 85 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 86 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 87 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 88 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143
TABLE 89 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 144
TABLE 90 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 144
11.2.1 US 144
11.2.1.1 Changes in reimbursement scenario to drive market growth 144
TABLE 91 US: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 145
TABLE 92 US: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 93 US: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 94 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
11.2.2 CANADA 147
11.2.2.1 Cancer is a leading cause of death in Canada 147
TABLE 95 CANADA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 148
TABLE 96 CANADA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 97 CANADA: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 98 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 149
11.3 EUROPE 149
TABLE 99 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 100 EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 150
TABLE 101 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 102 EUROPE: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 103 EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 104 EUROPE: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 105 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 106 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 107 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 108 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 153
TABLE 109 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 110 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 154
11.3.1 GERMANY 154
11.3.1.1 Availability of novel radiotherapy products drives market growth 154
TABLE 111 GERMANY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 155
TABLE 112 GERMANY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 113 GERMANY: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 114 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
11.3.2 FRANCE 157
11.3.2.1 High purchasing & maintenance costs of advanced radiotherapy systems limit market growth 157
TABLE 115 FRANCE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 157
TABLE 116 FRANCE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 117 FRANCE: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 158
TABLE 118 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 158
11.3.3 UK 158
11.3.3.1 High healthcare expenditure drives market growth 158
TABLE 119 UK: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 159
TABLE 120 UK: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 121 UK: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 160
TABLE 122 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 160
11.3.4 SPAIN 160
11.3.4.1 Growing research activities on cancer care support market growth 160
TABLE 123 SPAIN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 161
TABLE 124 SPAIN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 125 SPAIN: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 126 SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 162
11.3.5 ITALY 163
11.3.5.1 High number of oncology-specific clinical trials & studies support market growth 163
TABLE 127 ITALY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 163
TABLE 128 ITALY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 164
TABLE 129 ITALY: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 164
TABLE 130 ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 164
11.3.6 REST OF EUROPE 165
TABLE 131 ROE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 165
TABLE 132 ROE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 165
TABLE 133 ROE: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 134 ROE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 166
11.4 ASIA PACIFIC 166
FIGURE 27 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT 167
TABLE 135 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 136 ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 168
TABLE 137 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 138 ASIA PACIFIC: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 139 ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 140 ASIA PACIFIC: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 141 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 142 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 143 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 144 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 145 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 146 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 173
11.4.1 JAPAN 173
11.4.1.1 Rising geriatric population and incidence of cancer drive market 173
TABLE 147 JAPAN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 173
TABLE 148 JAPAN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 149 JAPAN: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 150 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 174
11.4.2 CHINA 175
11.4.2.1 Growing partnerships among market players to support growth 175
TABLE 151 CHINA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 175
TABLE 152 CHINA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 153 CHINA: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 154 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
11.4.3 INDIA 177
11.4.3.1 High need for radiotherapy systems to provide market opportunities 177
TABLE 155 INDIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 177
TABLE 156 INDIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 178
TABLE 157 INDIA: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 178
TABLE 158 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 178
11.4.4 SOUTH KOREA 179
11.4.4.1 Increasing incidence of cancer to support market 179
TABLE 159 SOUTH KOREA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 179
TABLE 160 SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 161 SOUTH KOREA: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 162 SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
11.4.5 AUSTRALIA 181
11.4.5.1 Availability of funding for cancer care & research to drive growth 181
TABLE 163 AUSTRALIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 181
TABLE 164 AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 165 AUSTRALIA: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 166 AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
11.4.6 REST OF ASIA PACIFIC 183
TABLE 167 ROAPAC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 183
TABLE 168 ROAPAC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 169 ROAPAC: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 170 ROAPAC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 184
11.5 LATIN AMERICA 185
TABLE 171 LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 185
TABLE 172 LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 185
TABLE 173 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 174 LATIN AMERICA: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 175 LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 176 LATIN AMERICA: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 177 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 178 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 179 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 180 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 189
TABLE 181 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 189
TABLE 182 LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 190
11.5.1 BRAZIL 190
11.5.1.1 Restricted affordability & access to radiotherapy treatment challenges market growth 190
TABLE 183 BRAZIL: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 190
TABLE 184 BRAZIL: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 185 BRAZIL: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 191
TABLE 186 BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 191
11.5.2 MEXICO 192
11.5.2.1 Rising target population drives market growth in Mexico 192
TABLE 187 MEXICO: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 192
TABLE 188 MEXICO: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 189 MEXICO: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 190 MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
11.5.3 REST OF LATIN AMERICA 194
TABLE 191 ROLATAM: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 194
TABLE 192 ROLATAM: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 193 ROLATAM: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 194 ROLATAM: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
11.6 MIDDLE EAST & AFRICA 195
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH 195
TABLE 195 MEA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 196
TABLE 196 MEA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 197 MEA: LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 198 MEA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 199 MEA: PARTICLE THERAPY SYSTEMS MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 200 MEA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 201 MEA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 202 MEA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 203 MEA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 199
TABLE 204 MEA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 200
TABLE 205 MEA: RADIOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 200

ページTOPに戻る

Table of Contents

Summary

The global radiotherapy market is valued at USD 6.3 billion in 2022 and is expected to reach USD 8.1 billion by 2027, at a CAGR of 5.1% during the forecast period. Technological advancements in radiotherapy and the rising incidence of cancer are the major factors driving the growth of this market. Additionally, growing awareness of the benefits of radiotherapy and the increasing use of particle therapy for cancer treatment are other factors driving the growth of this market. However, inadequate healthcare infrastructure, especially in emerging countries and shortage of skilled oncologists and radiologists hinders the growth of this market. In addition to this, high cost of radiotherapy devices, and high complexities associated with radiotherapy treatment are the factors expected to restrain the growth of this market during the forecast period.

“Theservice segment, by type, is expected to register the highest growth rate in the global radiotherapy market during the forecast period 2022-2027”
Based on type, the radiotherapy market is segmented into products and services. In 2021, the products segment accounted for the largest market share while the service segment is forecasted to grow with a higher growth rate during 2022-2027.The service segment includes post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services. The service market segment is expected to register higher CAGR especially in matured markets like North America and Europe.

“The Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators subsegment ofLinear Accelerators, within the external beam radiotherapy, to register a significant growth rateduring the forecast period”
On the basis oftechnology, the radiotherapy market is segmented into external beam radiotherapy, internal beam radiotherapy/brachytherapy, and systemic radiotherapy products. The external beam radiotherapy products segment is further divided into linear accelerators, particle therapy systems, and conventional cobalt-60 teletherapy units. The internal beam radiotherapy/brachytherapy products segment includes seeds, applicators, afterloaders, and IORT systems. The linear accelerators or LINAC segment is further characterized by conventional LINAC systems and stereotactic advanced electron/cobalt-60 LINAC systems. The Stereotactic advanced LINAC systems segment is expected to register the highest growth rate amongst linear accelerators segment. These systems provide precise 3D localization of the treatment target for various oncology procedures. The major objective of advanced LINAC systems is to expose the tumor to a single high dose of radiation while minimizing exposure to healthy surrounding structures. These systems can provide high precision and reduced treatment time with real-time tracking features which further supports the adoption of these systems.

“Continuous product development and launchesto drive the segment growthof particle therapy technology segment”
Based on technology, the radiotherapy market has been segmented into external beam radiotherapy and internal beam radiotherapy. The particle therapy subsegment of external beam radiotherapy is expected to grow with the highest growth rate amongst other segments of external beam radiotherapy (including linear accelerators, and conventional cobalt-60 teletherapy units). Continuous product development and R&D activities are also driving the growth of this market segment. Several particle therapy products have been launched in the market in the last three years. For example, Varian Medical Systems, Inc. (US), now under Siemens Healthineers AG (Germany), launched the ProBeam 360° single-room proton therapy system in 2018 and introduced a multi-room configuration for the same product in 2019. In April 2020, P-Cure (Israel) received CE marking for the P-ARTIS System, enabling the company to market and sell the product in Europe.

“The China market, by region, is expected to grow with the highest growth rate in the global rdaiotherpay market during the forecast period of 2022-2027”
On the basis of region, the radiotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific held the third largest share of the global radiotherapy market in 2021. Within Asia Pacific, China is expected to grow with the highest CAGR during the forecast period. The growth of this market is primarily driven by the favorable healthcare reforms and investments in the country. Owing to the growth potential of the Chinese radiotherapy market, various players are undertaking strategic initiatives to strengthen their presence in the country. These players include Mevion Medical Systems, IBA, Accuray, and Varian, which entered into partnerships, licensing deals, agreements, and cooperation framework agreements with various end users and stakeholders in China, to increase market presence in the country..

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type:Tier 1–30%, Tier 2–42%, and Tier 3– 28%
• By Designation: C-level–10%, Director-level–76%, and Others–14%
• By Region:North America–40%, Europe–30%, Asia Pacific–22%, Latin America–6%, and the Middle East & Africa–2%

The dominant players in the global radiotherapy market are Siemens Healthineers AG (Germany), Elekta (Sweden) Accuray Incorporated (US), IBA (Belgium), ViewRay Technologies, Inc. (US), Hitachi Ltd. (Japan), iCAD, Inc. (US), IsoRay, Inc. (US), Mevion Medical Systems, Inc. (US), Panacea Medical Technologies Pvt. Ltd. (India), P-cure Ltd. (Israel), and ZEISS Group (Germany), among others.

Research Coverage

This report studies the radiotherapymarket based ontype, technology, procedure, application, end user, and region. It also coversthe factors affecting market growth,analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Market Penetration:Comprehensive information on the product portfolios offered by the top players in the radiotherapymarket
 Product Development/Innovation:Detailed insights on the upcoming trends, R&D activities, and product launches in the radiotherapymarket
 Market Development:Comprehensive information on lucrative emerging regions
 Market Diversification:Exhaustive information about new products, growing geographies, and recent developments in the radiotherapymarket
 Competitive Assessment:In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（一般医療機器）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（hospital）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（一般医療機器）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（hospital）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?